John A. Ambrose, M.D., F.A.C.C.
John A. Ambrose is Professor of Medicine at New York Medical College, Valhalla, NY. He obtained his medical degree from New York Medical College and completed his internship and residency in internal medicine and a fellowship in cardiology at Mount Sinai Hospital, NY. Dr. Ambrose held positions with increasing responsibilities at Mount Sinai Medical Center and the New York Medical College, NY. He also served as Medical Director of the Comprehensive Cardiovascular Center and Chief of Cardiology at Saint Vincent Catholic Medical Centers, NY. Dr Ambrose is a working interventional cardiologist and has published more than 100 articles in the field of cardiology specializing on the mechanism of unstable angina and myocardial infarction. He is a member of several professional organizations and serves as President of the New York State Chapter of the American College of Cardiology and President of the New York Cardiologic Society. He also serves on the American College of Cardiology - Annual Scientific Session Program Committee, the New York State Department of Health - Cardiac Advisory Board and on the editorial boards of Cardio Intervention and Revista Cardiologist. Among honors received, the New York Medical College Alumni Association awarded him the Gold Medal of Honor. He received a National Leadership Award from the National Republican Congressional Committee and was Honorary Co-Chairman for the Physicians Advisory Board of the National Republican Congressional Committee.

Mark W. Frampton, M.D., F.A.C.P.
Mark W. Frampton is Professor of Medicine and Environmental Medicine at the University of Rochester, New York. He obtained his medical degree from New York University and completed his internship and residency in Internal Medicine at Buffalo General Hospital, Buffalo, New York. Dr. Frampton completed his fellowship at the Pulmonary and Critical Care Unit, University of Rochester, New York. He has worked as a visiting scientist at the Environmental Protection Agency and has held a faculty position at the University of Rochester since 1988. He is Director of the Pulmonary and Critical Care Fellowship Program and is Director of the Pulmonary Function Laboratory at Strong Memorial Hospital, New York. Dr. Frampton is also attending physician at Strong Memorial Hospital, New York, and Highland Hospital, New York. His research activities focus on the effects of particulate exposure on lung function, airway inflammation, and cardiovascular function including the effect of ultrafine particle exposure on endothelial function. He is a member of the American Thoracic Society where he is past Chair of the Environmental and Occupational Health Assembly and the Section on Terrorism and Inhalation Disasters. He is also a member and past President of the New York State Thoracic Society. Dr. Frampton serves on the editorial board of Inhalation Toxicology and Particle and Fibre Toxicology. He has served on various national advisory and health councils and research review committees and as a consultant to numerous health and science agencies.

James P. Kehrer, Ph.D.
James P. Kehrer is the Dean of the College of Pharmacy at Washington State University. He received his Ph.D. in Pharmacology and Toxicology from the University of Iowa, College of Medicine and completed postdoctoral work in toxicology in the Biology Division of Oak Ridge National Laboratory. He then held various positions with increasing responsibilities at the University of Texas at Austin, including 13 years as the Head of the Division of Pharmacology and Toxicology in the College of Pharmacy. He was Director of the Center for Molecular and Cellular Toxicology from 2003-2005 when he moved to Washington State University. In addition, Dr. Kehrer is a member of the US EPA Science Advisory Board Environmental Health Committee. Dr. Kehrer's research focuses on the mechanisms by which cyclooxygenase-2 inhibitors exert chemopreventive and anticancer activities. He is particularly interested in determining the basis for the selective toxicity to tumor cells, and also the roles of thioredoxin, glutathione, oxidized lipid species, and free radicals in signaling pathways related to apoptosis. Dr. Kehrer has authored more than 134 scientific publications and has published one book. He serves as editor for the Americas and Japan Toxicology Letters, Deputy Chairman of the editorial board for the Biochemical Journal and is on the editorial board for Archives of Biochemistry and Biophysics. Dr. Kehrer is a member of several professional organizations including the Society of Toxicology, American Association of Cancer Research, American Association for the Advancement of Science, and American Society for Pharmacology and Experimental Therapeutics where he is Chairman of the Toxicology Division.

Loren D. Koller, D.V.M., Ph.D., A.T.S.
Loren D. Koller is President of Loren Koller & Associates, LLC and specializes in Environmental Health and Toxicology. He received his D.V.M. from Washington State University and Ph.D. from the University of Wisconsin. Dr. Koller has over 30 years experience as a researcher in the areas of Pathology, Toxicology, Immunology, Carcinogenesis, and Nutrition. He was previously employed as Head of Diagnostic and Comparative Pathology at the National Institute of Environmental Health Sciences and has held academic positions with increasing responsibility at the University of Idaho and Oregon State University where he served as Professor and Dean of the College of Veterinary Medicine for 10 years. He has published in numerous refereed journals, served on several editorial boards, grant review panels, and as a consultant to government, business, and private firms on numerous occasions. Dr. Koller has been engaged in biomedical environmental research relating to health effects in humans most of his career. He has experience and knowledge in agriculture, biomedicine, and environmental health, with an appreciation and sensitivity of the issues involved in developing federal regulations. He has been invited to serve on committees for the National Cancer Institute, National Academy of Sciences (National Research Council and Institute of Medicine), Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, US Army, Environmental Protection Agency, and on the National Advisory Committee to Establish Acute Exposure Guidelines for Hazardous Substances. Dr. Koller is also a member of the Association for Assessment and Accreditation of Laboratory Animal Care International Board of Trustees, chaired an International of Environmental Issues in Veterinary Medical Education Workshop, participated in a meeting for the US Army's Institute for Defense Analysis, and served on as Expert Panel on Health Effects of Polychlorinated Biphenyl's for the Commonwealth of Massachusetts. He was President of the Society of Toxicology's Immunotoxicology Specialty Section and founding President of that organization's Veterinary Specialty Section. Dr. Koller is Fellow of the Academy of Toxicological Science.

John F. Lechner, Ph.D.
John F. Lechner is a Senior Research Scientist at the Ohio State University Comprehensive Cancer Center. He received his B.S. in agriculture from Cornell University, Ithaca, NY and Ph.D. in microbiology from Hahnemann University, Philadelphia, PA. Previous to his current position, Dr. Lechner served as Diagnostic Director for Oncology Programs with Bayer Diagnostics, Berkeley, CA. Prior to that he was Professor of Oncology/Pathology/ Pharmaceutical Sciences at Wayne State University School of Medicine, and as Chief of the Aerodigestive Carcinogenesis Program at Karmanos Cancer Institute. His research interests include the molecular mechanisms of disease detection, carcinogenesis mechanisms, and the management of research. He has published more than 140 articles and 1 book. Dr. Lechner is reviewing editor for In Vitro Cellular and Developmental Biology and is ad hoc reviewer of numerous cancer journals. He is a member of many professional associations including the American Association of Cancer Research, American Society for Cell Biology, and American Association of Pathologists. He has also provided consultant services to public agencies, foundations, professional associations and private enterprises.

Russell P. Tracy, Ph.D.
Dr. Tracy obtained his Ph.D. in Biochemistry at Syracuse University and did post-doctoral work at the Mayo Clinic in Clinical Chemistry and Protein Biochemistry. He is a Board-certified Clinical Chemist, and has directed clinical chemistry laboratories at Strong Memorial Hospital in Rochester NY and Fletcher Allen Health Care in Burlington VT. He currently holds the positions of Professor of Pathology and Biochemistry and Senior Associate Dean of Research & Academic Affairs at the University of Vermont, College of Medicine, Burlington. His research interests include the interrelationships of coagulation, fibrinolysis and inflammation, especially the innate and adaptive immune systems. He explores their roles in the etiology of atherosclerosis and coronary heart disease, insulin resistance and diabetes, and more broadly in chronic diseases of aging, using both biomarkers and animal models. He has a long standing interest in CVD risk modeling and risk assessment. He also collaborates on studies of murine models of atherosclerosis. Current epidemiological studies include the Cardiovascular Health Study, the Health, Aging and Body Composition Study, and the Multi-Ethnic Study of Atherosclerosis; his laboratory also performs core lab work for clinical trials in the area of heart disease. His laboratory acts as a biological sample repository, currently housing over 100 -80°C freezers and close to 3 million samples of serum, plasma, cells and DNA.